By Billy Candra 
Physicians caring for the growing population of childhood cancer survivors later in life must increasingly recognize that the intricate interplay of survivors’ genetic predispositions, alongside their life-saving initial cancer treatments, significantly contributes to their heightened risk for secondary cancers. This critical insight emerges from groundbreaking research conducted by scientists at St. Jude Children’s Research Hospital, who have meticulously quantified the proportional contributions of various factors to the likelihood of developing a subsequent malignancy. Secondary cancers, tragically, represent the leading cause of mortality for individuals who have successfully navigated childhood cancer and achieved long-term survival. The seminal findings, published today in the prestigious journal The Lancet Oncology, leverage the unparalleled depth of data from two of the world’s foremost childhood cancer survivor studies: the St. Jude Lifetime Cohort Study (St. Jude LIFE) and the Childhood Cancer Survivor Study (CCSS), both centrally housed at St. Jude.
The remarkable advancements in pediatric oncology over the past several decades have dramatically transformed the landscape for children diagnosed with cancer. What was once a near-certain death sentence for many has evolved into a disease with an overall survival rate now exceeding 80% across various cancer types. This medical triumph, however, has simultaneously given rise to a new and complex challenge: managing the long-term health consequences faced by this ever-expanding cohort of survivors. With an estimated half a million childhood cancer survivors currently living in the United States alone, and this number projected to grow, understanding and mitigating their unique health risks has become a paramount public health concern. Among these risks, the development of secondary cancers stands out as particularly devastating, often striking decades after the initial diagnosis and treatment, and posing a significant threat to their extended lifespans.
A Deep Dive into the Study’s Genesis and Methodology
For years, clinicians and researchers have acknowledged a link between certain childhood cancer treatments and an increased risk of secondary cancers. Similarly, a nascent understanding of genetic susceptibilities has been emerging. However, the precise proportional contribution of these factors at a population level remained largely unquantified, creating a critical knowledge gap in clinical guidance and risk stratification. Dr. Yadav Sapkota, a corresponding author from St. Jude’s Department of Epidemiology and Cancer Control, articulated the study’s core finding, stating, "We found the burden of second cancer in survivors of childhood cancer is largely contributed by pediatric treatment exposures and genetic predisposition. We’ve known treatment exposures and genetics were associated with second cancer risk, but this is the first time we’ve been able to attribute the proportion of their contributions to that risk at the population level."
To address this intricate challenge, St. Jude scientists embarked on an ambitious comparative analysis, examining data from over 10,000 survivors drawn from the St. Jude LIFE and CCSS cohorts. These two studies, collectively representing the largest survivor cohort in North America, provide an invaluable repository of longitudinal health information. The St. Jude LIFE study, established in 2007, meticulously tracks thousands of adult survivors treated at St. Jude, gathering comprehensive data on their health, treatment exposures, and genetic profiles. Complementing this, the CCSS, initiated in 1994, is a multi-institutional study that follows a much larger group of survivors from dozens of cancer centers across North America, allowing for broader epidemiological insights. The combined dataset meticulously included detailed records of initial treatment exposures, long-term health outcomes, extensive genetic information, self-reported lifestyle factors, and, crucially, the confirmed presence or absence of a second primary cancer. This holistic data integration enabled researchers to perform a robust evaluation of each factor’s contribution to the occurrence of subsequent malignancies.
Dr. Greg Armstrong, chair of St. Jude’s Department of Epidemiology and Cancer Control and a co-author on the study, underscored the unique capabilities afforded by these cohorts. "This kind of high-impact discovery is only possible in the CCSS and SJLIFE cohorts, that in combination, have more than 12,000 survivors with genetic sequencing," he noted, highlighting the sheer scale and detailed genetic information that were instrumental in this groundbreaking analysis.
Quantifying the Impact of Treatment Exposures: Radiation and Chemotherapy
The study’s findings reinforced long-held suspicions about the significant role of therapeutic radiation in increasing secondary cancer risk, while also providing a precise quantification. Radiation exposure emerged as the most significant single contributor, accounting for approximately 40% or more of the overall risk for developing a second primary cancer. This finding aligns with extensive prior research that has consistently documented the long-term adverse effects of radiation on healthy tissues, including its carcinogenic potential. In response to these known risks, modern pediatric oncology practices have, over time, progressively reduced radiation doses or, where possible, eliminated radiation entirely as other, equally effective treatment modalities became available. This evolution in care, driven by a deeper understanding of long-term sequelae, receives strong further support from the current study’s quantitative evidence. The emphasis on minimizing radiation exposure wherever clinically feasible continues to be a cornerstone of contemporary childhood cancer treatment protocols.
While the impact of radiation was stark and relatively straightforward, the researchers uncovered more nuanced and complex relationships concerning chemotherapy and genetic predisposition. Chemotherapy, a broad category encompassing numerous drugs with diverse mechanisms of action, contributed variably to subsequent cancer risk, ranging from 8% to 35% depending on the specific type of secondary cancer. The potential late effects of various chemotherapeutic agents, including cardiotoxicity, infertility, and neurocognitive deficits, have been extensively documented over the years. However, the precise population-level contribution of chemotherapy to secondary cancer risk, relative to other factors, had not been as clearly delineated until now.
The Unexpected Weight of Genetic Predisposition
Perhaps one of the most striking revelations of the study was the significant and, in some cases, surprising contribution of genetic predisposition to secondary cancer risk. While the late effects of radiation and chemotherapy have been the subject of considerable focus, the role of inherited genetic vulnerabilities in this specific context has been less thoroughly recognized and quantified. To delve deeper into this predisposition, the research team employed a sophisticated approach, examining hundreds of common genetic variants previously associated with cancer development in the general population. This was done by calculating a polygenic risk score (PRS) for each survivor. A PRS is a cumulative measure that aggregates the effects of many common genetic variants, each contributing a small amount to an individual’s overall risk for a particular disease. In addition to common variants, the study also considered the impact of certain rare genetic variants. The researchers then analyzed the relationship between these genetic scores and the occurrence of secondary cancers within the St. Jude LIFE and CCSS participant cohorts.
The polygenic risk score approach revealed a substantial contribution: depending on the specific type of secondary cancer, the PRS accounted for 5% to 37% of the total risk. This finding is particularly noteworthy because, as Dr. Yutaka Yasui, also from St. Jude’s Department of Epidemiology and Cancer Control and a co-author, explained, "Polygenic risk scores are developed for all kinds of diseases for personalized medicine, but generally with precision below what is required for clinical utility in the general population." However, in the unique context of childhood cancer survivors and for estimating their risk of certain types of subsequent cancers, Dr. Yasui suggested, "they may provide useful information in conjunction with therapy exposures."
Dr. Sapkota underscored the significance of this genetic insight, stating, "Our findings showed that genetics can be equally or more important than chemotherapy in some second cancers, which is counter to conventional wisdom in the field." This revelation challenges long-standing assumptions in oncology, suggesting that a survivor’s inherent genetic blueprint plays a far more substantial role in their long-term cancer risk than previously appreciated, sometimes even outweighing the impact of the very treatments that saved their lives.
Reassessing the Role of Lifestyle Factors
In contrast to the substantial contributions of treatment exposures and genetics, lifestyle factors such as diet, physical activity, and tobacco use appeared to contribute much less to secondary cancer risk within the studied population, accounting for a modest 1% to 6% of the risk. This finding, while initially counterintuitive given the well-established links between lifestyle and cancer risk in the general population, comes with an important caveat. The survivors included in this study were primarily in their 20s and 30s, an age range where the cumulative effects of lifestyle choices on cancer development may not yet have fully manifested. Many cancers linked to lifestyle factors, such as colon cancer or lung cancer, typically develop over decades of exposure.
Dr. Sapkota provided crucial context for this observation. "We know healthy lifestyle choices are important for survivors," he emphasized. "In this study, we focused only on the risk of second cancers, which may not be strongly impacted by lifestyle at this young age. However, other research has shown the benefits of healthy choices on other late effects, such as protecting cardiac well-being, so it is still important for clinicians to encourage — and patients to seek — a healthy lifestyle." This clarification ensures that the study’s finding on lifestyle is not misinterpreted as downplaying the overall importance of healthy habits for survivors, but rather highlights a potential age-dependent influence on secondary cancer development.
Transforming Clinical Care and Future Directives for Survivors
The implications of this comprehensive quantification are profound and are poised to reshape the paradigm of long-term care for childhood cancer survivors. "Historically, we have paid attention to survivors’ treatment exposures when determining second cancer risk," Dr. Sapkota noted. "Our study suggests that we need to better account for genetic predisposition in this population."
This paradigm shift necessitates a more personalized approach to survivorship care. Individuals identified with a strong genetic predisposition, either through specific rare variants or a high polygenic risk score, could potentially benefit from more regular and intense cancer screenings. This proactive surveillance strategy, tailored to their unique risk profile, would aim to detect a second cancer at its earliest, most treatable stages, significantly improving the chances of a favorable outcome. Furthermore, empowering survivors with knowledge of their individual combination of treatment-related, genetic, and lifestyle risk factors could enable them to become more informed advocates for their own health, facilitating more targeted discussions with their healthcare providers about appropriate screening and preventive measures.
The overarching goal of this research is to extend and enhance the lives of childhood cancer survivors. "Second cancers remain the leading cause of mortality for childhood cancer survivors," Dr. Sapkota reiterated. "Now that we have quantified the contributions of treatment, genetics, and lifestyle to the risk of secondary disease, we have a better understanding of where to focus efforts to prevent, detect, and treat these cancers, and hopefully extend these survivors’ lives." This understanding paves the way for the development of more precise risk assessment tools, targeted surveillance guidelines, and potentially even novel preventive strategies informed by an individual’s genetic makeup.
The journey of a childhood cancer survivor is a testament to resilience and the extraordinary progress of medical science. However, it is also a journey often fraught with long-term health challenges. This landmark study by St. Jude Children’s Research Hospital represents a significant leap forward in understanding and addressing one of the most formidable of these challenges: secondary cancers. By illuminating the complex interplay of treatment exposures and genetic vulnerabilities, the research provides a clearer roadmap for personalized medicine, offering hope for a future where these survivors can not only live longer but also live healthier, more fulfilling lives. The collaborative spirit demonstrated by the St. Jude LIFE and CCSS cohorts, along with their extensive data, continues to be an invaluable resource in the ongoing quest to improve outcomes for this special population.
Authorship and Funding Acknowledgements
The study’s meticulous execution was led by first author Achal Neupane, affiliated with St. Jude. The extensive list of contributing authors from St. Jude includes Siddhant Taneja, Jennifer French, Matthew Ehrhardt, Tara Brinkman, Rachel Webster, Jun Yang, Kirsten Ness, Melissa Hudson, Gregory Armstrong, Leslie Robison, and Yutaka Yasui. Additional contributions came from Qi Liu of the University of Alberta; Cindy Im, Lucie Turcotte, and Joseph Neglia of the University of Minnesota; Monica Gramatges of Baylor College of Medicine; Rebecca Howell of the University of Texas MD Anderson Cancer Center; and Smita Bhatia of the University of Alabama at Birmingham.
This pivotal research was made possible through substantial support from various institutions. Grants were provided by the National Cancer Institute (R01HL173881, R01CA216354, R21CA261833, U24CA55727, U01CA195547, and CA21765), along with generous funding from ALSAC, the dedicated fundraising and awareness organization for St. Jude Children’s Research Hospital. These contributions underscore the collaborative and well-resourced effort required to conduct research of such profound public health significance.
